Press Releases

Investors
<picture><source type="image/webp" srcSet="/static/6787a7fe95394de1d39fa6999021ab2f/83510/Investors_1-5-scaled.webp 640w,/static/6787a7fe95394de1d39fa6999021ab2f/9d163/Investors_1-5-scaled.webp 1280w,/static/6787a7fe95394de1d39fa6999021ab2f/ace97/Investors_1-5-scaled.webp 2560w" sizes="(min-width: 2560px) 2560px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2560px) 2560px, 100vw" decoding="async" loading="lazy" src="/static/6787a7fe95394de1d39fa6999021ab2f/6f033/Investors_1-5-scaled.jpg" srcSet="/static/6787a7fe95394de1d39fa6999021ab2f/1b145/Investors_1-5-scaled.jpg 640w,/static/6787a7fe95394de1d39fa6999021ab2f/73c00/Investors_1-5-scaled.jpg 1280w,/static/6787a7fe95394de1d39fa6999021ab2f/6f033/Investors_1-5-scaled.jpg 2560w" alt="&lt;p&gt;Surfer woman with longboard surfboard at Famara beach in Lanzarote Canary Islands&lt;/p&gt;
"/></picture>
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Overview
Press releases
Events & presentations
Corporate presentation
Events
Corporate Governance
Articles of Association
General meeting
Corporate governance reports
Senior executives
Nomination committee
Remuneration and the remuneration committee
Auditors and audit committee
Scientific committee
Shareholder & stock info
Share monitor
Shareholders
Analyst coverage
Financial reports
Financial calendar
Archived transactions
Rights Issue and Directed Issue 2023
Convertible bonds
Archive
Press releasesAll
2024
2024
23 July 2024
Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas
Press ReleaseStockholm, Sweden, July 23, 2024Mendus AB (“Mendus” publ; IMMU.ST) announces that it has entered into a collaboration with Institut Bergonié, a leading cancer center in Bordeaux, France to study the Mendus’ intratumoral immune primer ilixadencel in soft tissue sarcomas as
Learn more
28 June 2024Regulatory Release
Change in number of shares and votes in Mendus AB (publ)
Press ReleaseStockholm, Sweden, June 28, 2024As previously announced, the Annual General Meeting of Mendus AB (publ) (“Mendus”) on May 17, 2024, resolved on a reverse share split, whereby twenty (20) existing shares were consolidated into one (1) new share.As a result thereof, the number of
Learn more
20 June 2024
ALISON trial data presented at ESMO Gynaecological Cancers demonstrate tumor-directed immune responses in the majority of patients treated with vididencel
Press Release Stockholm, Sweden, June 20, 2024Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announces that updated clinical data from the ALISON clinical trial with its lead product vididencel in ovarian cancer
Learn more
17 June 2024
Mendus data presented at EHA substantiate the potential of vididencel to induce functional, clinically relevant immune responses in AML
Press releaseStockholm, Sweden, June 17, 2024ALL PATIENTS WITH CONFIRMED TUMOR ANTIGEN-SPECIFIC T CELL REPONSES FOLLOWING VIDIDENCEL TREATMENT REMAIN ALIVE IN LONG-TERM FOLLOW-UPMendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor
Learn more
3 June 2024
Mendus to participate in upcoming industry conferences
Press releaseStockholm, Sweden, June 3, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry conferences in June:BIO International ConventionSan
Learn more
28 May 2024Regulatory Release
Reverse share split in Mendus AB (publ)
Learn more
17 May 2024Regulatory Release
Report from the Annual General Meeting of Mendus AB (publ) on 17 May 2024
Press ReleaseStockholm, Sweden, May 17, 2024At the annual general meeting (the “AGM”) of Mendus AB (publ), reg. no. 556629-1786, (the “Company”), on 17 May 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions
Learn more
17 May 2024Regulatory Release
Mendus AB Interim Report January – March 2024
Learn more
16 May 2024
Mendus announces presentation of multiple abstracts during the 2024 CIMT Annual Meeting
Press ReleaseStockholm, Sweden, May 16, 2024 UPDATED CLINICAL DATA FROM THE ADVANCE II TRIAL DEMONSTRATE THE POTENTIAL OF VIDIDENCEL TO INDUCE EFFECTIVE T CELL RESPONSES AND IMPROVE OVERALL IMMUNE STATUS IN ACUTE MYELOID LEUKEMIAMendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company
Learn more
14 May 2024
Invitation to presentation of Mendus’ first quarter report 2024
Mendus AB (“Mendus” publ; IMMU.ST), will publish its interim report for the first quarter 2024 on Friday May 17 at 08:00 CEST. The company will host a live presentation the same day at 14:00 CEST. The call will be hosted by CEO Erik Manting and CFO Lotta Ferm. The presentation will be held in English
Learn more
For an overview of all press releases in connection with the Negma financing agreement, please go to Convertible bonds.